TokenPost·
Bernstein Moves Alnylam to Market Perform Over Nucresiran Trial Concerns
The change concerns TRITON-CM, a Phase 3 trial of nucresiran, Alnylam's next-generation RNAi therapeutic.
More news
- TokenPostMeta, Alphabet and Intel Slip Below Recent Stock Offering Prices
- Crypto BriefingOpenAI’s early 2027 report claim lands in a year already packed with AI predictions
- TokenPostTwilio Forecasts Q4 Organic Revenue Growth of 11% to 12%
- TokenPostMorgan Stanley ETF Wallets Send About $106 Million in Bitcoin to Coinbase Prime
- CoinGapeSolana Adds Hong Kong Dollar Stablecoin HKDAP for Payments and Tokenized Assets
- TokenPostBinance CEO Richard Teng Confirms Hackers Used EIP-7702 Delegation